BrightSpring Q2 Earnings Call Highlights Growth and Raised Outlook

Management’s message centered on execution across Pharmacy Solutions and Provider Services, while lower leverage and strong cash generation are creating more flexibility for acquisitions and other growth investments.

BTSG Raises 2026 Guidance

Executive vice president and CFO Jennifer Phipps raised full-year revenue guidance to $15.1-$15.425 billion, implying 17-19.5% growth over the figure for 2025 on a continuing-operations basis.

Phipps also lifted adjusted EBITDA guidance to $820-$845 million, representing 32.8-36.8% growth. The outlook includes about $35 million of 2026 adjusted EBITDA from acquired Amedisys and LHC branches.

Chairman, president and CEO Jon Rousseau said second-half momentum is broad-based. Phipps added that adjusted EBITDA should continue growing sequentially through the third and fourth quarter at similar quarter-to-quarter rates.

BrightSpring Pharmacy Mix Supports Margins

Rousseau said Specialty and Infusion remained central growth engines, with revenues up 30% and scripts up 31% year over year. BrightSpring launched 12 limited-distribution drugs through the second quarter, including four exclusive and eight ultra-narrow arrangements.

Phipps said Pharmacy Solutions adjusted EBITDA rose 44% to $180 million, with margin expanding about 80 basis points to 5.3%. Management pointed to branded LDD performance, product mix, pharma services and operational improvements.

In Q&A, a Morgan Stanley analyst asked about the sharp improvement in gross profit per script. Rousseau said mix and expanding fee-for-service offerings are important drivers, with those services now a meaningful top-three or top-four contributor to Pharmacy margins.

BTSG Provider Growth Broadens

Phipps said Provider Services revenues increased 30% to $466 million, while adjusted EBITDA grew 33% to $75 million. Home Health Care revenues rose 51% to $278 million.

The acquired Amedisys and LHC branches contributed about $78 million of revenues and $8 million of adjusted EBITDA in the second quarter. Phipps said integration progress and stronger volume supported the higher full-year EBITDA expectation for those assets.

Rousseau also highlighted de novo expansion, preferred MA and ACO contracts, and strong quality metrics as drivers of Home Health growth. He added organic Provider EBITDA growth was just under 20%.

BrightSpring Balance Sheet Adds Flexibility

Phipps said leverage ended the second quarter at 2.15x after BrightSpring repaid roughly $300 million of term debt. The company expects leverage below 2x by year-end before any acquisitions.

Rousseau said operating cash flow should be about $600 million for 2026. Excluding a roughly $100 million one-time tax payment tied to the Community Living divestiture, second-quarter operating cash flow was $144 million.

A UBS analyst asked whether the improved balance sheet could support more M&A. Phipps said the company has substantial flexibility, while Rousseau described a robust pipeline but stressed discipline, particularly as some market valuations reach more than 20 times EBITDA.

BTSG Q&A Tests Pharmacy Headwinds

A Mizuho analyst questioned the sequential decline in Pharmacy gross margin. Rousseau said the first quarter benefited from normal seasonality and maintained that second-quarter profitability was healthy, with gross profit per script higher after normalization.

A BMO Capital Markets analyst focused on IRA-related pressure. Phipps said Home and Community Pharmacy faces about $200 million of 2026 revenue impact, with roughly $15 million of EBITDA impact.

For 2027, Phipps said the current view for Home and Community Pharmacy is about half the 2026 IRA effect. Rousseau emphasized continued work on technology, automation and payer contracting to offset pressures management can influence.

BrightSpring Keeps Execution at the Center

Rousseau framed quality, operational discipline and patient-service performance as the foundation for growth across the platform. Management continues investing in automation, AI, hiring, onboarding and clinical workflows while expanding selected service lines.

The call also reinforced a disciplined capital-allocation posture. BrightSpring intends to pursue tuck-in acquisitions and geographic expansion while maintaining operating standards and balance-sheet flexibility.

BTSG’s Zacks Signals Remain Favorable

BTSG sports a Zacks Rank #1 (Strong Buy), along with a Value Score of B and Growth, Momentum and VGM Scores of A. Under the Zacks Style Scores framework, A and B grades are the preferred scores, particularly when paired with a Zacks Rank #1 or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

That combination places BTSG within the profile Zacks identifies as favorable for potential near-term performance across multiple investing styles. However, the Zacks Rank can change as analysts revise earnings estimates following the just-reported results.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research